Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Iterum closes $65mm Series B

Executive Summary

Infectious disease-focused Iterum Therapeutics Ltd. raised $65mm through its Series B financing led by Arix Bioscience, which was joined by other first-time backers Pivotal bioVenture Partners, Advent Life Sciences, Domain Associates, and Bay City Capital along with returning shareholders Frazier Healthcare Partners, Canaan Partners, Sofinnova Ventures, and New Leaf Venture Partners. The company will use some of the funds for Phase III trials (expected in H1 2018) of its sulopenem antibiotic for uncomplicated urinary tract infections and will also put funds towards production of clinical supplies and registration batches. A representative from Arix, Pivotal, and Advent will join the board.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies